Myeloproliferative Neoplasms: Polycythemia Vera


Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Rami Komrokji, MD: Let’s move to the next disease, polycythemia vera [PV]. Jamile, can you walk us through how you establish the diagnosis and risk stratify those patients?

Jamile Shammo, MD, FACP, FASCP: Sure. Polycythemia vera is a disease that typically manifests with erythrocytosis, or I should say blood count abnormalities. Typically patients will have bone marrow biopsies that will present with panmyelosis. It isn’t just erythrocytosis. It could also present with leukocytosis and thrombocytosis. A fraction of patients will have splenomegaly. About 30% to 40% may present as such. Some patients will present with thrombotic events. The very first presentation will be like Budd-Chiari [syndrome], but that typically isn’t the most common presentation. We should think about this disease when someone presents with a high hemoglobin and high hematocrit without a plausible explanation, essentially in someone who doesn’t have any other reason for secondary erythrocytosis.

The first test that I typically order for men with a hemoglobin above 16.5 g/dL and women with a hemoglobin above 16 g/dL is a JAK2 V617F mutation as well as a baseline serum EPO [erythropoietin] level. If the EPO level is low and the JAK2 mutation is positive, then you have a very good reason to believe that this is PV. Granted, if the hemoglobin is 18.5 or 18 g/dL, then you could probably forgo a bone marrow biopsy. If the numbers don’t necessarily match, then a bone marrow biopsy is needed. If the V617F mutation is negative, then exon 12 mutation should be ordered, even though it only represents about 3% [of cases].

Nowadays, the diagnosis of PV is much easier because 95% of the patients will be positive for a JAK2 mutation. If you added exon 12 to that, almost 99% will be positive. In cases where you’re entertaining the diagnosis of masked PV, in case there’s iron deficiency, you might want to rely on a bone marrow biopsy to make sure you’re also ruling out other myeloproliferative neoplasms [MPNs] that could have overlapping features. Sometimes patients may have a bit of fibrosis. It’s been said that people with PV who have a bit of fibrosis on their bone marrow may have somewhat of a worse outcome, but that remains to be seen. That’s pretty much how we make a diagnosis.

Rami Komrokji, MD: One of the key factors that you alluded to is that the threshold for diagnosis has been lowered in the new criteria for the cutoff of 16 and 16.5 g/dL rather than the old category where we used to look at masked PV. That helped with diagnosing a lot of patients.

Jamile Shammo, MD, FACP, FASCP: It surprises me that there’s no reference to iron parameters. One thing that I do all the time when I get a bone marrow biopsy is I get an iron stain. A lot of times, iron is absent and the diagnosis is ET [essential thrombocythemia]. How is that possible? That has to be somehow accounted for whenever a bone marrow biopsy is done for MPNs or with the consideration of MPN.

Transcript edited for clarity.

Related Videos
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Mikkael A. Sekeres, MD, MS
Naseema Gangat, MBBS